Downstaging with atezolizumab-bevacizumab: a case series.

ABSTRACT:

Backgrounds/aims

Hepatocellular carcinoma (HCC) is generally diagnosed at an advanced stage, which limits curative treatment options for these patients. Locoregional therapy (LRT) is the standard approach to bridge and downstage unresectable HCC for liver transplantation (LT). Atezolizumab-bevacizumab (atezo-bev) can induce objective responses in nearly one-third of patients; however, the role and outcomes of downstaging using atezo-bev remains unknown.

Methods

In this retrospective single-center study, we included consecutive patients between November 2020 and August 2023, who received atezo-bev with or without LRT and were subsequently considered for resection/LT after downstaging.

Results

Of the 115 patients who received atezo-bev, 12 patients (10.4%) achieved comp

SUBMITTER: Kulkarni AV 

PROVIDER: S-EPMC11449572 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature